Breaking News, Collaborations & Alliances

BioCentriq Completes Tech Transfer From Avenge Bio

Initiates manufacturing of clinical grade material to support Avenge Bio's ongoing phase 1/2 clinical trial for AVB-001.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BioCentriq, a New Jersey-based, cell and gene therapy contract development and manufacturing organization (CDMO), has successfully completed tech transfer of AVB-001 from client Avenge Bio and initiated manufacturing of clinical grade material, which will support Avenge Bio’s ongoing phase 1/2 clinical trial. Additionally, Avenge Bio announced on the January 9, 2023, that they successfully dosed the first patient in a first-in-human phase 1/2 clinical trial evaluating AVB-001 in relapse...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters